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Spinal muscular atrophy (SMA) is one of the most common juvenile neurodegenerative diseases, which can be associated with child
mortality. SMA is caused by a mutation of ubiquitously expressed gene, Survival Motor Neuron1 (SMN1), leading to reduced SMN
protein and the motor neuron death. The disease is incurable and the only therapeutic strategy to follow is to improve the
expression of SMN protein levels in motor neurons. Signiﬁcant numbers of motor neurons in SMA mice and SMA cultures are
caspase positive with condensed nuclei, suggesting that these cells are prone to a process of cell death called apoptosis. Searching
for other potential molecules or signaling pathways that are neuroprotective for central nervous system (CNS) insults is essential for
widening the scope of developmental medicine. PTEN, a Phosphatase and Tensin homologue, is a tumor suppressor, which is
widely expressed in CNS. PTEN depletion activates anti-apoptotic factors and it is evident that the pathway plays an important
protective role in many neurodegenerative disorders. It functions as a negative regulator of PIP3/AKT pathway and thereby
modulates its downstream cellular functions through lipid phosphatase activity. Moreover, previous reports from our group
demonstrated that, PTEN depletion using viral vector delivery system in SMN delta7 mice reduces disease pathology, with
signiﬁcant rescue on survival rate and the body weight of the SMA mice. Thus knockdown/depletion/mutation of PTEN and
manipulation of PTEN medicated Akt/PKB signaling pathway may represent an important therapeutic strategy to promote motor
neuron survival in SMA.
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INTRODUCTION
Spinal muscular atrophy (SMA) is a neuromuscular disorder caused
by reduced Survival motor neuron (SMN) protein levels. It is an
autosomal recessive pediatric neurological disorder characterized
by motor neuron degeneration, muscle wasting and paralysis that
can progress very rapidly to early childhood death.1–3 SMA is
classiﬁed into four types, based on the manifested clinical
symptoms and the age of onset.4 Type-1 is the most common
form characterized by severe, generalized muscular weakness and
hypotonia. It can cause problems in movement, eating, breathing
and inability to sit without support. Death from respiratory failure
usually occurs within ﬁrst few years. Type-2 usually appears in an
infant with the age of about 7–18 months. Children affected by
type-2 SMA are usually able to sit, but cannot stand or walk
without a proper support. They have breathing difﬁculties and
shorter life expectancy. Type-3 is a milder form of the disease, and
the symptoms may not appear until 18 months of age. Children
with type-3 SMA can stand and walk unaided but developing
muscle weakness eventually leads to inability to stand or walk.
This type of the disease does not usually affect the life expectancy.
Type-4 is adult onset and is less frequent than the other types. The
symptoms including muscle weakness and movement difﬁculties
are very mild and life expectancy is unaffected.
SMN is an essential cellular protein. The 38 kDa SMN protein is
expressed both in cytoplasm and the nucleus of many cell types
and is involved in many aspects of RNA metabolism.5 The protein
is a part of SMN complex with gemin proteins and plays an
important role in small nuclear ribonucleoprotein (SnRNP)
biogenesis and pre-mRNA splicing,6–8 it is still unclear why in
SMA the SMN deﬁciency speciﬁcally affects motor neurons.
Though the speciﬁc vulnerability of motor neurons is still
unknown, it has been suggested that SMN requirement is higher
in motor neurons than the other tissues due to its function in
splicing of the transcripts required specially for motor neuron
differentiation, neural development and axonal transport.9,10 The
interaction of SMN with hnRNPs delivers β-actin to presynaptic
nerve terminals, which is essential for axonal elongation and
determining the size of growth cone. The amount of β-actin mRNA
and protein at axonal terminals and growth cones is signiﬁcantly
reduced in severe SMA mice, suggesting the role of SMN in
transport and local translation of axonal mRNA at synaptic
terminals.11
SMN SPLICING AND SPLICE VARIANTS
There are two identical copies of SMN genes, SMN1 and SMN2 in
humans.12 But homozygous deletion, rearrangement or mutation
of SMN1 is the major cause of the disease in patients.12 Though
SMN1 and SMN2 have the capacity to encode a functional protein,
only SMN1 acts as a protein-determining gene. A silent non-
polymorphic nucleotide difference (C to T substitution) at position
six of Exon 7 (Ex7+6) in SMN2 disturbs splice enhancer in 4 90%
of SMN2 transcripts, which ultimately leads to alternative splicing
and truncated unstable protein lacking exon 7 called SMN delta7.
The exonic splicing enhancer (ESE) in SMN1 is recognized by
positive splicing factor 2 (SF2) or alternative splicing factor (ASF).
In SMN1, SF2/ASF interaction with U2 class of small ribonuclear
protein (U2 snRNP) under the inﬂuence of positive splicing factors
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such as SR rich proteins and Tra2, maintain the Exon7 inclusion.
Whereas in SMN2 the C to T substitution favors binding of a
negative splicing factor known as heterogeneous nuclear ribo-
nuclear protein A1 (hnRNP A1). So SF2/ASF no longer recognize
the enhancer sequence and fail to interact with other positive
splicing factors resulting a SMN2 mRNA transcript without
Exon7.13 This biochemically defective splicing event of SMN2
produces considerably less protein (o10%), which is not
sufﬁcient to sustain the survival and function of motor neurons.
Thus, in the absence of SMN1 the severity of disease pathology
mainly depends on SMN2 copy number.14 Keeping this in mind, a
number of strategies have been developed recently to induce
Exon7 inclusion in SMN2. One of these is the introduction of
bifunctional RNAs to increase the SMN splicing efﬁciency. During
SMN2 splicing, binding of hnRNP-A1 to the 5′ end of Exon7
decreases the splicing efﬁciency at acceptor site. Bifuctional RNAs,
in which one domain carries an antisense RNA sequence speciﬁc
to a target RNA (hnRNP-A1) and the other domain provide binding
platform for splicing factors (SF2/ASF, hTra2beta1), increase the
splicing efﬁciency. Using in vivo delivery system, plasmid based
recombinant Adeno-associated virus vectors (rAAV) have been
designed to express bifunctional RNAs to stimulate SMN2 Exon7
inclusion and functional SMN protein expression in patient
ﬁbroblasts.15 In contrast to humans, mice and other mammalian
species have a single SMN gene, which is equivalent to human
SMN1.16,17 Homozygous loss of this gene in mice is embryonic
lethal, indicating the necessity of SMN gene product for cell
survival and function. A mouse model suitable for human SMA
was developed by introducing a transgenic human SMN2 into
SMN null background.18 At birth, these animals have normal
neuromuscular system but with increasing age they develop
delayed NMJ maturation with neuroﬁlament (NF) aggregates,
reduced neurotransmitter release, failed acetylcholine receptor
(AChR) clustering and die with severe muscle paralysis within a
week or 10days of age.19,20 Introduction of two or more copies of
SMN2 in knockout background rescue the embryonic lethality and
survival respectively, suggesting the importance of SMN func-
tional role and also the signiﬁcance of the copy number.
NEURONAL CELL DEATH/APOPTOSIS IN SMA
SMA model systems and SMA cultures show a signiﬁcant decline
in motor neurons with increasing age and between 3 and
10 weeks of differentiation, respectively.21–23 The reason could be
either the developmental maturation error or death of motor
neurons over time. It is evident that greater number of SMA iPSC
differentiated motor neurons were caspase positive with a
signiﬁcant chromatin condensation compared to the controls
suggesting active apoptosis during motor neuron development or
maturation.22,24 Moreover, the neuronal apoptosis inhibitor
protein (NAIP) on chromosome 5 was mutated in a greater
number of SMA type 1 cases,25 suggesting a direct link between
apoptosis and SMA. Apoptosis is a complex process of pro-
grammed cell death, mediated by the activation of a family of
proteases known as caspases. The apoptotic cascades can be
triggered upon ligand binding such as TNF or FasL to their death
receptors TNFR or Fas, respectively. In mitochondria this cascade is
induced by intracellular stresses and by various proteins such as
Bcl-2, Bcl-c, Bax and the tumor suppressor p53. Using a murine
embryonic carcinoma cell line P19, a direct effect of SMN loss on
apoptotic cell death was observed.24 In SMN knocked down
differentiated P19 cell neurons the cell death was noticed as
caspase dependent, which is conﬁrmed by using pan-caspase
inhibitor ZVAD-fmk, which led to a signiﬁcant reduction in the rate
of apoptosis in SMN knocked down cells. In addition, the same
neurons also displayed intrinsic mitochondrial mediated
apoptosis.24 Cytochrome-c is a member of mitochondrial electron
transport chain and also a mediator of caspase cascade.
Cytochorme-c staining in differentiated P19 cell neurons displayed
patchy and clumped cytochrome c accumulation in cytoplasm
with condensed nucleus, while the control cells showed a
punctate distribution of cytochrome c with large smooth nuclei,
indicating an intrinsic mitochondrial apoptosis in RNAi treated
cells. Similar to this, in another study where the author used
iPSCells generated from a couple of type-1 SMA patients. One
produced with lentiviral constructs and the other using a virus-
free plasmid based approach.22 Both the iPSC lines have
signiﬁcantly fewer motor neurons at later stages of differentiation
compared to control iPSC-derived motor neurons. The cultures
showed an increase in the activation of Fas ligand mediated
apoptotic pathway through caspase-8 and caspase-3. Blocking this
pathway by using anti-Fas monoclonal antibody (Fas NT Ab) and
caspase-3 speciﬁc inhibitor Z-DVED-FMK signiﬁcantly increase the
motor neuron number,22 suggesting that apoptosis plays an
important role in SMA pathology and therapies targeting this
cascade may have signiﬁcant clinical applications.
SMA DISEASE PATHOLOGY AND THERAPEUTIC STRATEGIES
Though initially it was considered as a speciﬁc motor neuron
disease recent studies revealed that the disease is not speciﬁc to
motor neurons rather is a multi organ disorder.26,27 This is due to
the involvement of other neuronal population and vital organ
systems in SMA disease pathology. Various studies provided
evidences that the neurodegenerative disorder in SMA is also due
to loss of sensory neurons, inter neurons and disturbed astrocytic
function.28,29 Moreover, there was an evidential claim that the
activation of morphological and cellular alteration of astrocytes in
SMN delta7 mouse and SMA-induced pluripotent stem cells are
prior to motor neuron loss.29 Viral vector based restoration of SMN
protein in astrocytes increases the survival and neuromuscular
connections in SMA models indicating a direct contribution of
astrocytes to the disease pathogenesis.30 In SMA, the disease
pathogenesis also includes a severe muscle phenotype such as a
signiﬁcant delay in muscle growth, muscle development and
maturation. In addition to this the muscle ﬁbres are defective and
disorganized.31 This may be either a direct SMN deﬁciency effect
on muscle or an indirect effect through motor neuronal
dysfunction that contributes muscle atrophy. Cardiac system is
an important vital organ system to consider in SMA pathology.
This is due to the appearance of organ structural defects well in
advance of motor neuron dysfunction. Constant appearance of
congenital septal defects, arrhythmia and cardiomyopathy are the
most important cardiac phenotypes noticed in patients with
severe SMA and SMA mouse models.32,33 Adding to this vascular
defect such as distal digital necrosis, where the necrotic lesions
occur at the distal aspects of ﬁngers or toes are also commonly
reported in severe SMA patients.34 Viral delivery systems carrying
SMN (scAAV9-SMN) at the early post-natal stage prevented these
cardiac severe defects and signiﬁcantly improved the survival,
suggesting the role of SMN in cardiovascular system. Other organs
involved in SMA pathology are liver and pancreas. Abnormal fatty
acid metabolism, acute pancreatitis, diabetes and alterations in
glucose metabolism are some of the important pathological
defects noticed in SMA.35–37 Further, the story of SMA disease
pathology extended to bone as well. High incidence of fractures,
hypercalcemia and severe osteopenia are the important symp-
toms noticed in patients affected by SMA.38,39 Based on these
evidences it is clear that in addition to motor neurons, restoration
of SMN is required in many other cell and tissue types. Further
investigation is needed to improve the disease modifying
treatment for SMA.
SMA is currently incurable. This is because of the severity of
effects on the neuromuscular system and other organ systems
and lack of methods for efﬁcient delivery of therapeutically
functional molecules. Most of the drugs are still under clinical trials
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and as such there is no effective treatment of the disease so far. So
there is an essential requirement to identify the therapeutic
strategies that delay the advice of SMA pathology (Figure 1). Gene
therapy approaches using different viral vectors increases the
expression of the SMN and signiﬁcantly improve the survival in
mice.40,41 However, in order to get a signiﬁcant increase in SMN
gene expression, reduced disease pathology and improved
survival rate of the mice, the viral vectors must be delivered on
postnatal day1.42 The injections on postnatal day5 and day10 have
little or no effect respectively, suggesting that early detection and
the immediate therapy before noticing the clinical symptoms is
required. For that the early detection program and newborn
screenings must be established in order to avoid further
consequences.4 Though restoring SMN expression rescues early
lethality in SMA mouse model, there will be an adequate
requirement to ﬁnd out alternative mechanisms and molecular
pathways that provide additional protection to the motor neurons,
evade muscle degeneration and also to ﬁnd potential therapeutic
targets (Figure 1).
Recent studies on c-Jun NH2-terminal kinase 3 (JNK3) revealed
that this pathway mediates neurodegeneration in SMA. JNK3 is a
neuron speciﬁc isoform mediates neurodegeneration in SMA mice
caused by low SMN levels. JNK3 deﬁciency reduces the neuronal
degeneration and rescues the SMA phenotype without altering
levels of SMN. The deﬁciency also reduces the muscle atrophy,
improves muscle ﬁber thickness, the overall growth and the
lifespan of SMA mice.43 JNK3 represents a potential therapeutic
target for SMA treatment. The other important pathway involved
in SMA pathology is Ubiquitin signaling cascade. Dysregulated
ubiquitin homeostasis represents a key driver of both neuromus-
cular and systemic pathology in SMA.21,44 Ubiquitin activating
enzyme 1 (UBA1) is a part of ubiquitin protein degradation
pathway and also an important protein involved in neuronal cell
growth and differentiation. UBA1 suppression in iPSC derived
human SMA motor neurons, non-SMN dependent form of SMA in
human patients with UPA/UBA1 mutations45 and accumulation of
UPS target protein in SMA patients due to dysregulation of UPS/
UBA1 pathway46 suggesting UBA1 as an important and potentially
attractive therapeutic target for SMA. In addition to reduced levels
of UBA1 in SMA motor neurons, the cellular distribution of UBA1 is
also altered. UBA1 is localized mainly in the cytoplasm in contrast
to the nuclear distribution in control motor neurons. Nuclear
accumulation of UBA1 mainly correlates with neuronal maturation
and differentiation of motor neurons.21 In SMA motor neurons due
to cytoplasmic distribution of UBA1 there is a developmental
delay or abnormality in these cells. Ubiquitin Carboxyl-Terminal
Esterase L1 (UCHL1) is the other protein of UPS complex involved
in SMA pathology and it is also noticed as reduced in SMN motor
neurons derived from patient ﬁbroblasts. UCHL1 is involved in cell
machinery to degrade unwanted proteins and it has two types of
enzymatic activity. The hydrolase activity removes and recycles
the ubiquitin molecules from the degraded proteins whereas; the
ligase activity links the activity of ubiquitin molecules for use in
tagging proteins for disposal. Patients with loss of UCHL1
demonstrated early onset of neurodegeneration47 and exacerbate
disease symptoms in mouse model of SMA. Preliminary studies on
zebraﬁsh demonstrated UBA1 restoration rescue of the functional
and morphological neuromuscular defects of SMA ﬁsh.44 AAV9
mediated delivery of UBA1 in mice restores the gene levels,
rescues the neuromuscular defects, improves the body weight,
survival and motor performance. The AAV9-UBA1 treated SMA
mice also improved the systemic pathology in heart and liver.
Moreover, the study demonstrates the modest increase in the
expression of full-length SMN mRNA and SMN protein up on UBA1
delivery in SMA mice.44 Similar to JNK3 pathway and Ubiquitin
signaling cascade, here we proposed the PTEN mediated Akt/PKB
signaling pathway which plays an important role in axonal growth
and stability of motor neurons through the regulation of its
downstream cellular functions.
PTEN STRUCTURE AND SIGNALING PATHWAY
PTEN (a phosphatase and tensin homologue deleted on chromo-
some 10), is a tumor suppressor with both lipid and protein
phosphatase activities. PTEN structure consists of a Phosphatase
domain and a C2 domain responsible for its enzymatic function
and phospholipid membrane binding respectively (Figure 2). The
amino terminal end (N-ter) deﬁnes the catalytic activity of the
protein, whereas the carboxy terminal (C-ter) with PDZ domain
deals with protein-protein interactions.48
PTEN is highly expressed in the neurons of adult CNS. It is
localized both in the nucleus and the cytoplasm of neuronal and
glial cells.49 The expression of PTEN is ubiquitous and it is required
for cell proliferation, growth and migration from early embryonic
developmental stages. PTEN functions as a phosphatase to
dephosphorylate the phosphatidylinositol (3,4,5) tri phosphate
(PIP3) to phosphatidylinositol (4,5) bis-phosphate (PIP2).50 PIP3 is
an important primary activator of Akt/PKB, a serine/threonine
kinase pathway (Figure 3). PTEN inhibit Akt signal transduction
pathway and modulates its downstream cellular functions through
lipid phosphatase activity. Cell motility via small G proteins RAC1
and CDC42, also depending on PTEN lipid phosphatase activity.51
The downstream effect of increased PIP3 by PTEN inhibition
activates many pathways, which include mTOR mediated cellular
signaling;52 controlled apoptosis pathway either by transcriptional
regulation or by phosphorylation;53 neuronal polarity through
GSK3 inhibition;54 proliferation and self-renewal of various cell and
progenitor cell types;55 laminin and cytoskeletal protein
expression;56 glycolysis and glycogeneis;57 TGF-β and BMP
associated SMAD pathways.58 The protein phosphatase activity
Figure 1. Possible therapeutic strategies for SMA. The SMN
dependent strategies concentrating mainly on SMN2 gene expres-
sion, whereas the SMN independent treatment is concentrating on
different possible signaling pathways that are capable to modulate
the disease pathology in SMA.
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of PTEN includes, dephosphorylation of focal adhesion kinase
(FAK) in cytosol, Shc dephosphorylation, and the MAP kinase
activity through RAS/ERK pathway in the nucleus59 (Figure 3).
PTEN NEUROPROTECTION IN NEUROLOGICAL DISORDERS
Studies on gliomas and medulloblastomas raise the importance of
PTEN in developmental biology. Further, the germ line mutations
of this protein in brain disorders demonstrate the signiﬁcance of
PTEN in CNS and established a proper study model for
neurodegenerative diseases. PTEN mutations display brain dis-
orders such as macrocephaly, neuronal hypertrophy, seizures,
abnormal social interactions and mental retardation. On the other
hand recent reports clearly evidenced the PTEN-down-regulation
mediated neuro protection using both in vitro and in vivo model
systems. Brieﬂy, in Lou Gehrig’s disease popularly known as
amyotrophic lateral sclerosis (ALS), excitotoxicity is considered to
play a key role where, AMPA receptors allow cytotoxic levels of
calcium into motor neurons and contributes neuronal injury.60
GluR2, one of the heteromeric receptor complexes of AMPA
determines calcium permeability and selective death of MNs in
ALS. PTEN knock down in primary cultured motor neurons and
induced pluripotent stem cell (iPSC)-derived motor neurons
attenuates the death of these neurons by decreasing the
translocation of GluR2 receptor subunit into the membrane. This
study of induced pluripotent stem cells (iPSc) differentiated motor
neurons open gates to new approaches in ALS therapy.61 In age-
related neurodegenerative disorder like Parkinson’s disease,
oxidative stress due to PTEN accumulation in mitochondria
associated with Bax, cytochrome c and activated Caspase 3 leads
to mitophagy, which is the primary reason for neurodegeneration
in patients. Knockdown of PTEN inhibits Caspase 3 activation
through Akt signal transduction pathway and prevents neuronal
damage.53 Also, selective PTEN depletion in dopaminergic
neurons in mouse model of Parkinson’s disease exhibit more
extensive pattern of neurite outgrowth and are less susceptible to
cell death. The selective deletion of PTEN in dopamine neurons
enhances the survival, neurite outgrowth, function and integration
of grafted neurons with the host tissue.62 This strategy of
transplantation of modiﬁed neurons in to animals to improve
graft viability and function in cell replacement therapies are
promising.
In addition to its protective role after neuronal injury, PTEN
depletion or inactivation also enhances neurogenesis and
neuroregeneration. Failure of injured axons to regenerate in the
CNS leads to paralysis, which is the characteristic feature of spinal
cord injury. Regeneration usually takes place either by sprouting
spread of non-injured axon to form new circuits or regeneration of
lesion axon to reform the lost connections. Delivery of neuro-
trophic factors, removing extracellular inhibitory molecules63,64
Figure 3. Schematic presentation of suggested pathways of PTEN
involvement in neuronal survival. PTEN regulates the conversion of
Phosphatidylinositol (3,4,5) triphosphate into Phosphatidylinositol
(4,5) bis phosphate (PIP2). PTEN activation leads to cell spreading
and growth by inhibition or dephosphorylation of FAK1 (protein
tyrosine kinase 2) and SHC transforming protein 1 in cytoplasm and
by inhibiting cyclin D1 in the nucleus. PTEN depletion activate Akt
signaling pathway which in turn regulate all downstream cellular
effects such as cell growth, proliferation and cell survival. PTEN
depletion is sufﬁcient to trigger mammalian target of rapamycin
(mTOR) that alters downstream signaling pathways for local protein
synthesis by increasing P70s6 kinase activity. This pathway also
inﬂuences many apoptosis factors either by transcriptional regula-
tion or by direct phosphorylation.
Figure 2. PTEN structure. A structure of 403 amino acids with N-terminal, Phosphatase, C2 domains and the C-terminal tail. The N-terminal
domain contains PIP2 binding domain (PBD) and an important ubiquitination site K13 responsible for nuclear translocation. The Phosphatase
domain of PTEN is responsible for its protein and lipid phosphatase activities. The C2 domain is hosting p53-binding site, which is responsible
for PTEN apoptotic activity. Other important sites labeled with magenta are the phosphorylation sites both in C2 domain and the C-ter tail.
These residues are phosphorylated by Glycogen synthase kinase 3B (GSK3b) and casein kinase 2 (CK2). C-ter tail of PTEN is responsible for
protein stability and protein–protein interactions.
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and over expressing BDNF receptor TrkB65 can promote some
degree of regeneration but is limited. In cortical neurons axotomy
diminish mTOR activity, which is the central regulator of cap
dependent protein translation that leads to defective regenerative
ability in adult CNS. PTEN inactivation or deletion activates
downstream pathways, such as Akt and mTOR signaling in these
neurons and promotes protein synthesis for axonal
regeneration.54,66
PTEN DOWNREGULATION TO SMA PATHOGENESIS
The process of cell death named Apoptosis has been implicated in
many neurodegenerative diseases including SMA (Figure 4). Loss
of SMN1 leads to motor neuron cell death through apoptosis.54
Increased levels of membrane bound FasL, activation of Caspase-8
and Caspase-3 and chromatin condensation in SMA-iPSC differ-
entiated motor neurons provide a direct evidence of apoptosis in
SMA pathology.22 The lack of apoptosis in PTEN mutated tumors
raise the hope of this tumor suppressor gene in regulating
neuronal apoptosis during neurodegeneration. Recent literature
has shown that this tumor suppressor protein considered to be an
important target because of its neuro-protective effect51 and also
its controlling effect on Akt phosphorylation and its downstream
cellular functions. PTEN is a crucial mediator of mitochondria-
dependent apoptosis. Studies using Staurosporine (STS) induced
apoptotic damage in hippocampal neurons demonstrated that the
suppression of PTEN expression signiﬁcantly reduces the reactive
oxygen species (ROS) and interfered with mitochondrial apoptotic
cascade by inhibiting cytochrome c release and caspase 3
activation.53 They provided a clear evidence of direct association
of PTEN with Bax, the pro-apoptotic protein of Bcl-2 family
members. In addition to Bax, other pro-apoptotic factor p53 has
direct association with PTEN.50 Adding to that the C2 domain of
PTEN contains p53-binding site by which the cross talk taking
place during apoptosis.67 PTEN inhibition activates the anti-
apoptotic factors and plays a neuroprotective role in focal
ischemia and global cerebral ischemia.22 Gene therapy based
approaches of blocking Akt mediated apoptosis pathway through
PTEN depletion may become one of the possible therapeutic
strategies. Further studies on PTEN regulation through signal
transduction mechanism will be important and helpful in
developing therapeutic targets for SMA disease pathology and
other neuronal disorders.
Other important milestone of PTEN research is the identiﬁcation
of its ubiquitination sites, which are important for PTEN nuclear
translocation. During tumorigenesis, the reduced nuclear translo-
cation of PTEN impairs its tumor suppressing function, leading to
reduced apoptotic cell death, suggesting that PTEN nuclear
translocation is causally linked to its apoptotic activity.68 Though
PTEN has two important ubiquitination sites K13 and K289
(Figure 2) the C2 domain ubiquitination site PTENK289 neither is
involved in nuclear translocation nor in reducing apoptosis. PTEN
Mono-ubiquitination of PTEN at lysine-13 residue (K13) upon
excitotoxic stimulation of N-methyl-D-aspartate (NMDA) is required
for PTEN nuclear translocation in cultured neurons. It was
hypothesised that upon excitotoxic/ischemic brain insult, PTEN
may translocate to nucleus and its accumulation may cause
neuronal damage. Keeping this in mind Wang YT and colleagues
designed a short interfering peptide that ﬂanks K13 residue (tat-
K13), which may competitively inhibit PTEN mono ubiquitination
and hence block its nuclear translocation.69 PTEN tat-K13 peptide
reduces the NMDAR-mediated excitotoxicity and blocks PTEN
nuclear translocation in cultured neurons and protects against
ischemic brain injury in rats. The concept of preventing apoptosis
or neuronal death by blocking PTEN nuclear translocation is a new
concept and it may have broad implications in other neurode-
generative disorders including SMA.
Activation of Akt upon PTEN depletion triggers mTOR pathway,
which is sufﬁcient to raise β-actin and axonal growth in MNs. This
approach of PTEN depletion using viral vector in SMNdelta7 mice
achieved a substantial improvement of motor neuron survival and
represent an important therapeutic strategy to promote the
health of motor neurons in SMA and other motor neuron
diseases.70,71 Branchu et al.72, in their study demonstrated that
the drug inhibition of MEK/ERK/Elk-1 signaling pathway could be
beneﬁcial to study the severe types of SMA. Inhibition of
extracellular signal regulated kinase (ERK) pathway promotes the
PI3K/AKT/CREB pathway activation and increases the SMN
expression in SMA mice spinal cord and human SMA myotubes.
The activation of PI3K/AKT pathway also increases the lifespan of
SMA mice. MEK/ERK/Elk-1 and PI3K/AKT both recruit the cAMP
element binding protein (CREB), which is considered to be a
powerful activator of neuron pro survival transcription factor and
an efﬁcient trans activator of the SMN gene.73 This shift of ERK to
AKT is mediated by additional transcription factor CaMKII, which is
directly involved in AKT activation after ERK inhibition. CaMKII
mediated activation of AKT/CREB pathway is acting parallel to the
PTEN mediated PIP3/AKT pathway, which is considered to be one
of the targeting cascade of therapeutic applications. Interestingly
PTEN knockdown using scAAV9-siPTEN improved the motor
function of SMA mice and signiﬁcantly increase the lifespan in
SMA mice.70,71 Finally it is tempting to speculate that combined
delivery of siPTEN along with coSMN may show result in potential
improvement in disease pathology and will be helpful pharma-
cologically in drug development.
CONCLUSION
Disease models of SMA suggested that reduced SMN is the main
cause of disease pathology. Different model systems with a variety
of strategies improved the quality of selective spinal motor
neurons and also extended the lifespan in vivo. Therapeutic
approaches concentrating to raise the levels of SMN protein and
also for the betterment in screening methods in newborn. Parallel
to this other studies concentrating on intrinsic signaling pathways
to target the motor neuron quality control via regulation of
protein synthesis. Tumor suppressor protein PTEN is a negative
regulator of Akt phosporylation, is one of the promising
therapeutic target in developmental medicine. PTEN depletion
Figure 4. General overview of the process of cell death in SMA. The
activation of intrinsic and extrinsic apoptotic pathways up on
stimulation. The intrinsic pathway in mitochondria activates cell
death via caspase 8 and caspase 3. In extrinsic pathway the
activation of caspases is due to different signalling molecules such
as increased calcium, reactive oxygen species and excitotoxicity.
PTEN depletion activates PIP3/AKT signaling pathway that blocks
the caspase mediated apoptosis pathway.
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enhances the axonal growth and improves survival in SMN-
deﬁcient motor neurons. PTEN neuroprotective signaling presents
the possibility as a therapeutic target for SMA and other
neurodegenerative diseases. Next-generation therapeutic strate-
gies such as using combinatorial drug treatment may helpful in
drug discovery. And also further studies using a model system,
which is close to human disease model such as iPSCs will be
helpful to understand the disease pathology, molecular mechan-
ism, drug discovery, toxicology studies and therapeutic use.
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